These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth. Posuwan N, Wanlapakorn N, Vongpunsawad S, Sintusek P, Leuridan E, Van Damme P, Poovorawan Y. Vaccine; 2020 Feb 11; 38(7):1643-1651. PubMed ID: 31948817 [Abstract] [Full Text] [Related]
23. Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine. Gimenez-Sanchez F, Kieninger DM, Kueper K, Martinon-Torres F, Bernaola E, Diez-Domingo J, Steul K, Juergens C, Gurtman A, Giardina P, Liang JZ, Gruber WC, Emini EA, Scott DA, 501 and 006 study groups. Vaccine; 2011 Aug 11; 29(35):6042-8. PubMed ID: 21704105 [Abstract] [Full Text] [Related]
24. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Madhi SA, Koen A, Cutland C, Groome M, Santos-Lima E. Pediatr Infect Dis J; 2013 Aug 11; 32(8):889-97. PubMed ID: 23538523 [Abstract] [Full Text] [Related]
27. Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course in healthy Korean infants: phase III, randomized study. Kim KH, Kim CS, Kim HM, Kim JD, Ma SH, Kim DH, Hwang PH, Han JW, Lee TJ, Kim JH, Karkada N, Mesaros N, Sohn WY, Kim JH. Hum Vaccin Immunother; 2019 Aug 11; 15(2):317-326. PubMed ID: 30431387 [Abstract] [Full Text] [Related]
35. Safety and immunogenicity of a hexavalent DTwP-IPV-HB-PRP∼T vaccine versus separate DTwP-HB-PRP∼T and IPV vaccines in healthy infants in India. Mangarule S, Palkar S, Mitra M, Ravi MD, Dubey AP, Moureau A, Jayanth MV, Patel DM, Ravinuthala S, Jagga SR, Patnaik BN, Jordanov E, Noriega F. Vaccine X; 2022 Apr 11; 10():100137. PubMed ID: 35462885 [Abstract] [Full Text] [Related]
36. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Macías M, Lanata CF, Zambrano B, Gil AI, Amemiya I, Mispireta M, Ecker L, Santos-Lima E. Pediatr Infect Dis J; 2012 Aug 11; 31(8):e126-32. PubMed ID: 22531237 [Abstract] [Full Text] [Related]
38. Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants. Ruiz-Palacios GM, Guerrero ML, Hernández-Delgado L, Lavalle-Villalobos A, Casas-Muñoz A, Cervantes-Apolinar Y, Moreira M, Schuerman L. Hum Vaccin; 2011 Nov 11; 7(11):1137-45. PubMed ID: 22048109 [Abstract] [Full Text] [Related]
39. A Phase III Randomized, Double-blind, Clinical Trial of an Investigational Hexavalent Vaccine Given at Two, Three, Four and Twelve Months. Vesikari T, Becker T, Vertruyen AF, Poschet K, Flores SA, Pagnoni MF, Xu J, Liu GF, Stek JE, Boisnard F, Thomas S, Ziani E, Lee AW. Pediatr Infect Dis J; 2017 Feb 11; 36(2):209-215. PubMed ID: 27846055 [Abstract] [Full Text] [Related]